PharmiWeb.com - Global Pharma News & Resources

Press Releases - 2022-07-12

Date Title Company
12-Jul-2022 Kepler Vision Technologies launches international expansion with NESK partnership Kepler Vision Technologies
12-Jul-2022 DKSH and Pharmanovia Partner to Respond to Therapeutic Needs in Southeast Asia DKSH
12-Jul-2022 NAME HEATWAVES AS PART OF EARLY WARNING SYSTEM TO SAVE LIVES The Physiological Society
12-Jul-2022 HDR UK and Wellcome launch Biomedical Vacation Scholarship Programme 2022 HDR UK
12-Jul-2022 Endogena Therapeutics transitions into clinical stage with its novel regenerative treatment for blindness caused by retinitis pigmentosa Endogena Therapeutics
12-Jul-2022 ABB and Red Hat partner to deliver further scalable digital solutions across industrial edge and hybrid cloud ABB
12-Jul-2022 Yposkesi reinforces team with three executive appointments Andrew Lloyd Associates
12-Jul-2022 First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s) Businesswire
12-Jul-2022 Neuraxpharm to increase branded business through upcoming acquisition of established products from Sanofi Neuraxpharm
12-Jul-2022 vasopharm GmbH Announces Brain Lactate Microdialysate Data from Post Hoc Analyses of Clinical Trials in Traumatic Brain Injury vasopharm GmbH
12-Jul-2022 Destiny Pharma receives award from the Cystic Fibrosis Foundation Destiny Pharma
12-Jul-2022 Anjarium Biosciences appoints experienced industry executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer Anjarium Biosciences
12-Jul-2022 Genmab Major Shareholder Announcement Genmab
12-Jul-2022 No thromboembolic events or related serious adverse events reported over 12-week observation period in FRONTIER1 study.1 Novo Nordisk
12-Jul-2022 Provepharm receives FDA marketing approval in US for BLUDIGO, its indigo carmine injection drug product Andrew Lloyd Associates
12-Jul-2022 MODERNA’S OMICRON-CONTAINING BIVALENT BOOSTER CANDIDATE, mRNA-1273.214, DEMONSTRATES SIGNIFICANTLY HIGHER NEUTRALIZING ANTIBODY RESPONSE AGAINST OMICRON SUBVARIANTS BA.4/5 COMPARED TO CURRENTLY AUTHORIZED BOOSTER MODERNA
12-Jul-2022 Akili Announces Public Company Board of Director Nominees Akili Interactive
12-Jul-2022 Actigen Receives Positive FDA Response for Rare Disease Treatment Actigen
12-Jul-2022 Accelerate Diagnostics Announces Commercialization in Europe of its Accelerate Arc™ System Having Completed IVDR Registration Accelerate Diagnostics
12-Jul-2022 Data presented today show a reduction in treated spontaneous and traumatic bleeds and mean annualised bleeding rate (ABR) of 1.7 with concizumab1 Novo Nordisk